Bruker Reports Third Quarter 2019 Financial Results Q3-19 revenue growth of 11.7% and organic revenue growth of 7.6% year-over-year Q3-19 GAAP EPS of $0.39; Q3-19 non-GAAP EPS of $0.43, up 16.2% year-over-year Increasing

Reports Third Quarter 2019 Financial Results

BILLERICA, Massachusetts - October

31, 2019 - Bruker Corporation (Nasdaq: BRKR) today announced financial results for its third quarter and for the nine

months ended September 30, 2019.

Third Quarter 2019 Financial Results

Bruker's revenues for the third quarter of 2019 were $521.1

million, an increase of 11.7% compared to the third quarter of 2018. In the third quarter of 2019, Bruker's year-over-year

organic revenue growth was 7.6%. Growth from acquisitions was 6.4%, while foreign currency translation had a negative effect of

Third quarter 2019 Bruker Scientific Instruments (BSI) segment

revenues of $471.8 million increased 13.1% year-over-year, including organic growth of 8.6%. Third quarter 2019 Bruker Energy &

Supercon Technologies (BEST) segment revenues of $52.5 million increased 3.1% year-over-year, including an organic revenue decline

of 0.8%, net of intercompany eliminations.

Third quarter 2019 GAAP operating income was $87.8 million,

compared to $69.1 million in the third quarter of 2018, representing GAAP operating margins of 16.8% and 14.8%, respectively. Non-GAAP

operating income was $95.5 million, compared to $83.3 million in the third quarter of 2018. Bruker's third quarter 2019 non-GAAP

operating margin of 18.3% increased 40 basis points from 17.9% in the third quarter of 2018.

Third quarter 2019 GAAP diluted earnings per share (EPS) were

$0.39, compared to $0.28 in the third quarter of 2018. Non-GAAP EPS were $0.43, a 16.2% increase compared to $0.37 in the third

First Nine Months of 2019 Financial Results

For the first nine months of 2019, Bruker's revenues were

$1,472.7 million, an increase of 9.7% from $1,342.0 million in the first nine months of 2018. In the first nine months of 2019,

Bruker's organic revenue growth was 6.0% year-over-year. Growth

from acquisitions was 7.0%, while foreign currency translation had a negative effect of 3.3%.

In the first nine months of 2019, BSI segment revenues of $1,331.0

million increased 10.3% year-over-year, including organic growth of 5.8%. First nine months 2019 BEST segment revenues of $152.2

million increased 9.3% year-over-year, including organic growth of 7.0%, net of intercompany eliminations.

In the first nine months of 2019, GAAP operating income was

$183.2 million, compared to $156.0 million in the first nine months of 2018, representing GAAP operating margins of 12.4% and 11.6%,

respectively. Non-GAAP operating income was $231.5 million, compared to $195.1 million in the first nine months of 2018. Bruker's

non-GAAP operating margin in the first nine months of 2019 was 15.7%, an increase of 120 basis points, compared to 14.5% in the

first nine months of 2018.

In the first nine months of 2019, GAAP EPS were $0.82, compared

to $0.65 in the first nine months of 2018. Non-GAAP EPS were $1.04, an increase of 20.9% over $0.86 in the first nine months of

A reconciliation of non-GAAP to GAAP financial

measures is provided in the tables accompanying this press release.

Frank H. Laukien, President and CEO of Bruker, commented: "We

are very pleased with our year-to-date progress, with 6% organic and 13% constant currency revenue growth, highlighted by our strong

performance in life science mass spectrometry solutions and in microbiology. We are on track to deliver solid margin and EPS improvements

in 2019, and we are increasing our non-GAAP EPS outlook for the full year."

Fiscal Year (FY) 2019 Financial Outlook

For FY 2019, Bruker continues to expect year-over-year revenue

growth of 7.0% to 8.0%, which now includes the following estimates:

Bruker continues to expect non-GAAP operating margin expansion

in FY 2019 of 90 to 120 basis points over its FY 2018 non-GAAP operating margin of 16.8%. This now includes approximately 50 basis

points of foreign currency tailwind. Bruker is raising its FY 2019 non-GAAP EPS outlook to a range between $1.59 and $1.62, representing

a 13.5% to 15.5% increase compared to FY 2018.

For our outlook for FY 2019 non-GAAP operating margin and

non-GAAP EPS, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations

to such GAAP financial measures on a forward-looking basis. Please see "Use of Non-GAAP Financial Measures" below for

a description of items excluded from our expected non-GAAP operating margin and non-GAAP EPS.

Quarterly Earnings Call

host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters

today, October 31, at 4:30 p.m. Eastern Daylight Time. To listen to the webcast, investors can go to https://ir.bruker.com

and click on the "Q3 2019 Earnings Webcast" hyperlink. A slide presentation that will

be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins. Investors

can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (US toll free) or +1-412-317-6702 (international)

and referencing "Bruker's Third Quarter 2019 Earnings Conference Call". A telephone replay of the conference

call will be available by dialing 1-877-344-7529 (US toll free) or +1-412-317-0088 (international) and entering conference number:

10136323. The replay will be available beginning one hour after the end of the conference through December 1, 2019.

About Bruker Corporation (Nasdaq: BRKR)

scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's

high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and

materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation,

improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy

and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics

research and clinical microbiology. For more information, please visit: www.bruker.com.

Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are

prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial

measures in this press release or in the earnings webcast: organic revenue and revenue growth on a constant currency basis; non-GAAP

gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating profit; non-GAAP operating margin; non-GAAP

SG&A expense; non-GAAP profit before tax; non-GAAP tax rate; non-GAAP net income and non-GAAP earnings per share. These non-GAAP

measures exclude costs related to restructuring actions, acquisition and related integration expenses, amortization of acquired

intangible assets and other non-operational costs.

We also refer to organic revenue growth

and free cash flow in this press release or on the earnings webcast, which are also non-GAAP financial measures. We define the

term organic revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates and the effect of acquisitions

and divestitures, and believe it is a useful measure to evaluate our continuing business. Related to organic growth, we

also present constant currency information to provide a framework for assessing how our underlying businesses performed excluding

the effect of foreign currency rate fluctuations. To present this information, current and comparative prior period results for

entities reporting in currencies other than U.S. dollars are converted into U.S. dollars using the average exchange rates from

the comparative period rather than the actual exchange rates in effect during the respective periods. We define free cash

flow as net cash provided by operating activities less additions to property, plant, and equipment. We believe free cash flow

is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant,

and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return

of capital to shareholders.

The presentation of these non-GAAP financial measures is not

intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may

be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We

believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance, however we urge

investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying

tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP

measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in

our industry, as well as by our management, in assessing both consolidated and business unit performance.

We use these non-GAAP financial measures to evaluate our period-over-period

operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting

for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors

in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP